CD8A and melanoma: The combined administration of IL21 and IL15 dramatically increased the CD8+ T cells and resulted in tumor regression in mice melanoma models (98). Likewise, the combination treatment of IL21 with IL7 promotes the expansion of CAR-T cells with a TSCM phenotype (133).